Amendment No. 2 to Amended and Restated Clinical Collaboration and Supply AgreementClinical Collaboration and Supply Agreement • May 8th, 2024 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations
Reference is hereby made to the Clinical Collaboration and Supply Agreement, dated July 22, 2020, as amended via the Amended and Restated Clinical Collaboration and Supply Agreement, dated January 13, 2022, and the Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement, dated October 5, 2023 (collectively the “Agreement”), by and between Olema Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 780 Brannan Street, San Francisco, CA 94103 (“Olema”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation, having a place of business at 181 Massachusetts Avenue, Cambridge, MA 02139 (“Novartis”).
